MARCH Renal Substudy

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV. Antiretroviral therapy associated renal dysfunction has been predominantly described in terms of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur in the absence of significant reductions in eGFR. This substudy is an exploration of changes in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kirby Institute
• Treatments: Abacavir; Atazanavir Sulfate; Darunavir; Dideoxynucleosides; Emtricitabine; Fosamprenavir; HIV Protease Inhibitors; Lamivudine; Lopinavir; Maraviroc; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Zidovudine

Criteria

Inclusion Criteria:

• Provision of written, informed consent for participation in the substudy

• Enrolled into the substudy either at or before the week 0 visit of the main study